Patents Assigned to Oxigene, Inc.
  • Efficient method of synthesizing combretastatin A-4 prodrugs
    Patent number: 6743937
    Abstract: Methods of synthesizing a phosphate ester of combretastatin A-4 and trans-isomers thereof in which combretastatin A-4 is reacted with dibenzylphosphite in the presence of carbon tetrabromide, or with 2,2,2-trichloroethyl phosphorodichloridate, to form a phosphate ester of combretastatin A-4 with protecting groups thereon.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: June 1, 2004
    Assignee: OxiGene, Inc.
    Inventors: Faye Seyedi, Jonathan Gale, Reem Haider, John Hoare, Amy Baldwin
  • Use of aryl N-substituted carboxamides directly and as radio-and chemosensitizers for killing tumor and cancer cells and novel compounds for such use
    Patent number: 6713517
    Abstract: Methods of killing tumor or cancer cells in human patients using an aryl N-substituted carboxamide having one or more aryl halo or one or more aromatic nitrogens, and/or acid addition salts thereof. The carboxamide may be an N-substituted nicotinamide or an N-substituted benzamide having such features, and may be used directly as a chemotherapeutic agent, or as a sensitizer for radiation or other chemotherapeutic agents. New compositions for such use include N-(2-diethylamino-ethyl)-4-amino-3-chlorobenzamide, N-(2-diethylamino-ethyl) nicotinamide, and their acid addition salts, e.g. hydrochlorides.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: March 30, 2004
    Assignee: OXiGENE, Inc.
    Inventors: Ronald W. Pero, Anders Olsson, Tomas Ekberg, Alan Schwartz, David Chaplin
  • Compositions and methods for use in targeting vascular destruction
    Patent number: 6538038
    Abstract: Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: March 25, 2003
    Assignee: OXiGENE, Inc.
    Inventors: Ronald W. Pero, David Sherris
  • Uses of nicotinamide adenine dinucleotide and its derivatives for treatment of malignant and infectious diseases
    Patent number: 6339073
    Abstract: This invention provides a method of killing tumor cells or microorganisms which comprises contacting the tumor cells or the microorganisms with an amount of nicotinamide adenine dinucleotide (NAD) or its analogs effective to increase clonogenic toxicity of cells. This invention also provides a method of killing tumor cells or microoganisms in a subject which comprises administering an amount of nicotinamide adenine dinucleotide or its analogs effective to increase clonogenic toxicity of cells to the subject.
    Type: Grant
    Filed: September 9, 1998
    Date of Patent: January 15, 2002
    Assignee: Oxigene, Inc.
    Inventor: Ronald W. Pero
  • N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
    Patent number: 6100299
    Abstract: N-acetyl-3-chloroprocainamide, its acid addition salts, mixtures thereof, formulations containing the same for therapeutic administration to a human or other animal, and uses thereof in methods of inhibiting or killing tumor or cancer cells and in methods of treating inflammatory disorders.
    Type: Grant
    Filed: June 8, 1998
    Date of Patent: August 8, 2000
    Assignee: OXiGene, Inc.
    Inventor: Ronald W. Pero
  • Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
    Patent number: 6028111
    Abstract: The use of benzamide and nicotinamide analogs, in particular N-substituted benzamides and nicotinamides, other than benzamides with N-pyridinyl substitutions, as anti-inflammatory agents.
    Type: Grant
    Filed: February 27, 1997
    Date of Patent: February 22, 2000
    Assignee: OXiGENE, Inc.
    Inventors: Ronald W. Pero, David Chaplin
  • Carotenoid-nicotinamide-zinc compositions and methods of treatment using same
    Patent number: 6020351
    Abstract: Selectively administering to humans, as a daily dosage, a combination of carotenoids, nicotinamide (or niacin or a precursor thereof) and a source of zinc, in excess of normal dietary levels, for improving resistance to DNA damage, enhancing DNA repair capacity, and stimulating immune function.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: February 1, 2000
    Assignee: OXiGENE, Inc.
    Inventor: Ronald W. Pero
  • Methods of administering phenothiazines and/or acid addition salts thereof
    Patent number: 5561129
    Abstract: A method of administering phenothiazines and their acid addition salts. The phenothiazine or acid addition salt is injected intramuscularly in a formulation with a pH of about 5.5 to about 7.0 and at a concentration of at least about 50 mg/ml, to deliver a dose of one to 5 mg/kg. The drug is administered either in a formulation containing Na.sup.+ ions and at a pH adjusted to reduce extrapyramidal side effects or in a formulation essentially free of Na.sup.+ ions.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 1, 1996
    Assignee: OXiGENE, Inc.
    Inventor: Ronald W. Pero
  • Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
    Patent number: 5561161
    Abstract: A method of administering N-substituted benzamides, and their acid addition salts, in particular metoclopramide and its acid addition salts, is disclosed wherein the metoclopramide or acid addition salt is injected intramuscularly in a formulation with a pH of about 5.5 to about 7.0 and at a concentration of at least about 50 mg/ml, to deliver a dose of one to 5 mg/kg.
    Type: Grant
    Filed: March 25, 1994
    Date of Patent: October 1, 1996
    Assignee: OXiGENE, Inc.
    Inventor: Ronald W. Pero